(e) what is the composition of each; and

(f) what is the justification of increase in each case?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTIUZERS (SHRI CHINTA MOHAN) : (a) On the basis of a sample analysis it has been found that in only 12-13 cases of non-scheduled formulations, the prices have recorded an increase of more than 10% over their prices prevailing at the time of announcement of DPCO, 1987.

(b) Yes, Sir. to the extent possible.

(c) to (e) To the extent available, the information is given in the Annexure [See Appendix CLXV, Annexure No. 30]

(f) The matter would be examined.

Irregularities committed by M/s. Carews

1608. SHRIMATI KAILASH PATI : Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that M/s. Carews, an MRTP company, was liable to pay in respect of Combiflame and other products before November, 1986;

(b) what is the position of recovery against this company and what steps have taken to identify all the irregularities of this company;

(c) whether it is a fact that' all these irregularities were later on not pursued; and

(d) what steps have been taken to probe the entire issue?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTIUZERS (SHRI CHINTA MOHAN) : (a) to (d) M 's. Carews were ordered to deposit an amount of Rs. 710.27 lakhs on account of overcharging in respect of Combiflame for the period between 5-11-1986 to 31-12-1988. The company has filed a Writ Petition against the order in the Calcutta High Court. In respect of other products which were being manufactured by this Company during the disputed period, the issue whether there had been any irregularity, is under consideration.

Increase in drug prices without technical study

1609. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that his Ministry allowed price increases of certain drugs without cost-cum-tachnical study under DPCO, 1987;

(b) if so, names of those drugs and what was the increase allowed and the present price of each;

(c) whether it is a fact that the Ministry have not verified the stocks in hand, expected arrival and CIF import price of raw materials, and latest conversion norms before allowing price increases;

(d) if so, the names of those drugs and reasons therefor;

(e) whether it is a fact that these producers made huge unitended profits; and

(f) if so, what steps have been taken to assess and make recovery ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTIUZERS (SHRI CHINTA MOHAN) : (a) to (d) To the extent information is available, there are four bulk drugs in respect of which cost-cum-technical study reports of BICP are not available under DPCO 1987 and in whose cases price increases have been notified from time to time to accommodate increase in input costs and to avoid shortages. Details of names of these drugs and prices are given in the Statement at Statement (See below). The prices of these drugs have been worked out on the basis of analysis of consumption norms of raw materials and utilities and other cost data submitted by the manufacturers. No on-the-spot verification has been done. This kind of exercise is done by the BICP as part of their cost-cum-technicai study.

(e) There is no material to indicate that manufacturers made any unintended profits.

(f) Does not arise.

Statement

Sl. No.	Name of the bulk drug	Unit	Previous Price	Revised Price	Date
1.	Ampicillin Trihydrate	Kg.	1859.00	2054.00	6-9-88
			2054.00	1925.00	21-3-89
			1925.00	2216.00	9-10-91
			2216.00	2516.00	13-4-92
			2516.00	3098.00	27-7-92
2.	Ampicillin Anhydrous	Kg.	2368.00	2790.00	6-9-88
			2790.00	2631.00	21-3-89
			2631.00	3341.00	24-2-92
			3341.00	3599.00	27-7-92
3.	Amoxycillin Trihydrate	Kg.	2495.00	2865.00	6-9-88
			2865.00	2660.00	21-3-89
			2660.00	2093.00	11-2-91
			2093.00	2649.00	14-10-91
			2649.00	2922.00	13-3-92
			2922.00	3216.00	27-7-92
4.	Doxycycline	Kg.	5486.00	4968.00	9-8-80
			4968.00	5416.00	20-8-92

Amount Overcharged by M/s. Lyka Labs.

1610. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 734 given in Rajya Sabha on the 16th July, 1992 and state :

(a) what is the amount overcharged by M/s. Lyka Labs, on the Flucort range of formulations between 9th March and 13th July, 1990 and whether the total recoverable amount upto this period has been worked out;

(b) what is the magnitude of over charging and pack-wise earlier and revised prices of the formulations w.e.f. 12th October, 1990;

(c) when parawise comments were sent on the writ to the Government advocate in September, 1990; and

(d) what are the reasons for delay in filing of counter-affidavit and what steps have been taken to fix responsibility for the delay ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) The tentative liability into DPEA of M/s. Lyka Labs, in respect of Fluocinolone Acetonide has been worked out as Rs. 678.73 lakhs for the period from 1-4-1979 to 25-8-1987 on the basis of data furnished by the company regarding quantity *ot* bulk drng *consumed in*